Anticoagulant Therapy During Pregnancy for Maternal and Fetal Acquired and Inherited Thrombophilia
S. R. Giannubilo and A. L. Tranquilli
Pages 4562-4571 (10)
Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the
puerperium. Antithrombotic treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), lowmolecularweight
heparin (LMWH), Warfarin and Aspirin. The prevalence and severity of thromboembolism during pregnancy and
puerperium warrant special consideration of management and therapy. Such therapy includes the treatment of acute thrombotic events
and prophylaxis for those at increased risk of thrombotic events. This paper assesses the safety and efficacy of antithrombotic therapy
during pregnancy and the peripartum period. Its cardiovascular and obstetric indications, the evidence of association between
thrombophilias and adverse pregnancy outcome, regimens and maternal and fetal side-effects are also discussed.f
Anticoagulants, aspirin, heparin, pregnancy, thrombophilia, warfarin, MATERNAL, INHERITED, FETAL, hypercoagulability.
Department of Clinical Sciences, Polytechnic University of Marche, Salesi Hospital via F. Corridoni 11, 60123 Ancona, Italy.